CBSA and BIO Host Webinar: Developing + Distributing a COVID-19 Vaccine
By: Colorado BioScience Association Date: 10/26/2020
CBSA partnered with the Biotechnology Innovation Organization (BIO) to host a webinar about the ecosystem’s work to develop and deliver a safe and effective COVID-19 vaccine. The discussion featured a panel of experts that presented on the vaccine research, development and manufacturing that’s underway and highlighted the industry’s commitment to scientific rigor, transparency, and diversity.
- Michael Mullette, Vice President of North America Commercial Operations at Moderna, provided an update on the company’s work to develop a COVID-19 vaccine. Just last week, Moderna completed enrollment for their Phase 3 clinical trial and continues to scale up manufacturing to supply 500 million to 1 billion doses of their vaccine per year.
- Phyllis Arthur, Vice President for Infectious Diseases and Diagnostics Policy at BIO, gave an overview of the global pipeline and walked through how companies have been able to accelerate the development process. She also explained the framework for prioritizing populations and distributing a COVID-19 vaccine once it is approved by the FDA.
- Lastly, Andrew Powaleny, Director of Public Affairs at PhRMA, presented key takeaways from PhRMA’s work to understand vaccine hesitancy and build public confidence in a COVID-19 vaccine.
The webinar attracted over 50 attendees including Colorado state legislators, policymakers, CBSA members, and partners.
For those who were unable to join the webinar, you can view highlights of the discussion here.
You can also view select slides from the webinar presentations here.
Categories: CBSA News